The Role of Upper Gastrointestinal Swallow Study in Patients Undergoing Proximal or Total Gastrectomy

Igor Jeroukhimov MD, Natan Poluksht MD, Nava Siegelmann-Danieli MD, Ron Lavy MD, Ilan Wassermann MD, Zvi Halpern MD, Ruth Gold-Deutch MD and Ariel Halevy MD

Division of Surgery, Assaf Harofeh Medical Center, Zerifin, affiliated with Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel

ABSTRACT: Background: One of the ominous complications following proximal gastrectomy or total gastrectomy is a leak from the esophagogastric or esophagojejunal anastomosis. An upper gastrointestinal swallow study is traditionally performed to confirm the anastomotic patency and lack of any leak before oral feeding can be initiated.

Objectives: To challenge the routine use of UGISs following proximal or total gastrectomy in order to check the integrity of the gastroesophageal or jejunoesophageal anastomosis.

Methods: The charts of 99 patients who underwent PG or TG for malignant pathology were retrospectively reviewed. UGISs were performed on day 6 following surgery using a water-soluble material.

Results: The UGISs were normal in 95 patients, with none displaying any complication related to the gastroesophageal or jejunoesophageal anastomosis. All four patients who experienced a leak from the anastomosis had an early stormy postoperative course.

Conclusions: Routine use of an UGIS to detect a leak following PG or TG is not justified. UGIS should be performed whenever signs of abdominal sepsis develop following this type of surgery.

KEY WORDS: contrast upper gastrointestinal study, leak, proximal gastrectomy, total gastrectomy, malignant pathology

BACKGROUND: One of the ominous complications following proximal gastrectomy or total gastrectomy is a leak from the esophagogastric or esophagojejunal anastomosis. The reported rate of this complication varies between 1% and 29% [1-4] and is followed by a mortality rate of 14.4 to 50% [3,5-7].

An upper gastrointestinal swallow study is traditionally performed to confirm the anastomotic patency and lack of any leak before oral feeding can be initiated. Since the majority of UGISs performed in our patients were normal, we decided to challenge the need for the routine use of this study before initiation of oral feeding in asymptomatic patients following PG or TG surgery.

RESULTS: The study population consisted of 99 patients, 59 males and 40 females. The mean age was 63 ± 13.1 years. The underlying pathology was adenocarcinoma in 85%, gastrointestinal stromal tumor in 10%, lymphoma in 4% and carcinoid tumor in 1%. The tumor was located in the stomach in 78 patients and in the distal part of the esophagus in 21 (Siewert type II and III). Fifty TGs and 49 PGs were performed. All patients who underwent PG had a stapled esophagogastric anastomosis using a circular stapler of 25 mm diameter, while those
who underwent TG had a stapled esophagojejunostomy reconstruction performed either by Roux-Y (39 patients) or esophagojejunostomy plus a Braun modification enterostomy in 11 patients.

A feeding jejunostomy was constructed in 85 patients. Sixteen splenectomies (16%) were performed either for gastric tumor extension or as a result of incidental splenic injury. The mean packed red blood cell transfusion was 1.6 ± 1.5 units per patient. The mean operative time was 207 ± 39 min: 20 ± 28 min for the PG group and 213 ± 51 min for the TG group.

Twenty-two patients (22%) developed 28 different complications [Table 1]. Mean hospital stay was 17 ± 9 days. Four patients (4%) died. Cardiac events caused two perioperative deaths, and sepsis due to anastomotic leak resulted in another two deaths.

The UGISs were performed on day 6 ± 1 day following surgery. An anastomotic leak was revealed in four patients (4%). Three patients developed the leak following TG and one following PG. The anastomotic leak was confirmed by UGIS performed on day 5 ± 1. All four patients had clinical signs and symptoms of abdominal sepsis (one of these patients had a pancreatic fistula). Three of these patients underwent reoperation and two of them died. The fourth patient had a minimal leak and was managed conservatively. One of these four patients had a splenectomy performed during the initial surgery. There was no difference in the number of transfused blood units between patients who had a leak and those who did not.

All patients with a normal UGIS result started uneventful oral feeding following the diagnostic procedure.

### Table 1. Complications in study patients

<table>
<thead>
<tr>
<th>Complication</th>
<th>No. of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumonia</td>
<td>6</td>
</tr>
<tr>
<td>Intraabdominal abscess</td>
<td>5</td>
</tr>
<tr>
<td>Cardiac event</td>
<td>4</td>
</tr>
<tr>
<td>Anastomotic leak</td>
<td>4</td>
</tr>
<tr>
<td>Cerebral vascular event</td>
<td>2</td>
</tr>
<tr>
<td>Sepsis</td>
<td>2</td>
</tr>
<tr>
<td>Deep vein thrombosis/pulmonary emboli</td>
<td>1</td>
</tr>
<tr>
<td>Biliary fistula</td>
<td>1</td>
</tr>
<tr>
<td>Pancreatic fistula</td>
<td>1</td>
</tr>
<tr>
<td>Small bowel necrosis</td>
<td>1</td>
</tr>
<tr>
<td>Small bowel obstruction</td>
<td>1</td>
</tr>
</tbody>
</table>

DISCUSSION

A leak from an anastomosis following esophagogastrectomy is a fearful complication associated with increased morbidity and mortality [1-8]. Historically, and in current practice, the anastomotic patency has been radiographically studied before the initiation of oral feeding. Since most surgeons follow this traditional approach, it has not been changed for many years and recent publications report that this practice is still common [4-8]. However, there are surgeons who do not adhere to this routine and perform an UGIS only when a leak is clinically suspected [9-11]. Following the “tradition,” we performed an UGIS in each and every patient following PG and TG, but it was our impression that a patient whose postoperative course is uneventful will have no leak on UGIS, while in those patients with a difficult postoperative course and especially signs of abdominal sepsis an anastomotic leak will be diagnosed. In an attempt to test this hypothesis we performed this retrospective study.

Our study population included 99 patients who underwent major gastric surgery with construction of an esophagojejunostomy or esophagogastrectomy. Four patients had a leak diagnosed by UGIS, and all four patients had signs and symptoms of abdominal sepsis. In all four the study was performed on an emergency basis and three of the four were reoperated. The other 95 patients who had a smooth postoperative course had no evidence of a leak on a UGIS routinely performed on day 6 ± 1 following surgery.

Some points need further clarification, such as the day of performing the UGIS and the material used. There is no consensus regarding the day of UGIS performance. In some series the UGIS was performed on day 4 [3], while others performed the study on day 6 or even the 14th postoperative day [4-8]. In our series the study was scheduled for the 6th postoperative day. We believe that this period can be shortened to the 4th or 5th postoperative day since in most cases the leak develops during this period [4]. Another point is the contrast material to be used for the study. Most authors used water-soluble material [8]. However, in some studies the authors recommended the use of barium as it has been reported to have a lower false-negative rate [1,12,13]. Lamb et al. [4] used water-soluble contrast material first and if no leak was documented the study was repeated with barium.

Various authors agree that in patients having a smooth postoperative course no leak will be detected on UGIS, whereas patients demonstrating any signs of sepsis should undergo a UGIS as early as possible to detect a possible leak [4,9-11]. These findings also emerge very decisively from our study where all four patients with a leak had early signs of sepsis while the other 95 patients with an uneventful postoperative course had no leak on UGIS.

Our retrospective study does not support the routine use of a radiologic investigation of anastomotic patency and absence of a leak in asymptomatic patients following gastroesophageal surgery. However, patients with signs of sepsis, an abnormal perianastomotic drain discharge, or clinical deterioration should undergo an urgent contrast examination.
**Capsule**

**Type IIA topoisomerase inhibition by a new class of antibacterial agents**

Despite the success of genomics in identifying new essential bacterial genes, there is a lack of sustainable leads in antibacterial drug discovery to address increasing multidrug resistance. Type IIA topoisomerases cleave and relegate DNA to regulate DNA topology and are a major class of antibacterial and anticancer drug targets, yet there is no well-developed structural basis for understanding drug action. Bax and coworkers report the 2.1 Å crystal structure of a potent, new class, broad-spectrum antibacterial agent in complex with *Staphylococcus aureus* DNA gyrase and DNA, showing a new mode of inhibition that circumvents fluoroquinolone resistance in this clinically important drug target. The inhibitor ‘bridges’ the DNA and a transient non-catalytic pocket on the twofold axis at the GyrA dimer interface, and is close to the active sites and fluoroquinolone binding sites. In the inhibitor complex the active site seems poised to cleave the DNA, with a single metal ion observed between the TOPRIM (topoisomerase/primase) domain and the scissile phosphate. This work provides new insights into the mechanism of topoisomerase action and a platform for structure-based drug design of a new class of antibacterial agents against a clinically proven, but conformationally flexible, enzyme class. *Nature* 2010; 466: 935

Eitan Israeli

**Capsule**

**Fighting cancer with nanoparticles and laser**

Potential weapons against cancer are not limited to small-molecule drugs, with nanomaterials such as carbon nanotubes among other candidates. The latest hot material, graphene – single-atom-thick sheets of carbon – seems to home in on tumors and, with the help of a laser, can heat up and kill them from within. Liu and co-researchers coated nanometer-scale graphene sheets with polyethylene glycol to increase their solubility and stability in the body. They then injected the material into tumor-bearing mice and found high levels of graphene accumulation in their tumors after 24 hours. The team administered the graphene to another set of 10 mice with breast tumors and shone lasers at the growths. The tumors disappeared the following day and did not regrow during the 40 day experiment. Tumors in control mice that did not receive either the graphene or the laser treatment grew rapidly, killing the mice in about 16 days. *Nano Lett.* doi:10.1021/nl100996u (2010)

Eitan Israeli

“In youth we feel richer for every new illusion; in maturer years, for every one we lose”

Madame Anne Sophie Swetchine (1782-1857), Russian mystic